Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al Reply

被引：0

作者：

Hetland, Merete Lund ^{[1
,2
,3
,4
]}

Linde, Louise ^{[1
,2
,3
,4
]}

Christensen, Ib Jarle ^{[5
]}

Dreyer, Lene ^{[5
]}

Tarp, Ulrik ^{[6
]}

Hansen, Annette ^{[7
,8
]}

Hansen, Ib Tonder ^{[9
]}

Kollerup, Gina ^{[10
]}

Lindegaard, Hanne M. ^{[11
]}

Poulsen, Uta Engling ^{[12
]}

Schlemmer, Annette ^{[13
]}

Jensen, Dorte Vendelbo ^{[14
]}

Jensen, Signe ^{[8
]}

Hostenkamp, Gisela ^{[15
]}

Ostergaard, Mikkel ^{[3
,4
,8
]}

机构：

[1] DANBIO Registry, Hvidovre, Denmark

[2] DANBIO Registry, Glostrup, Denmark

[3] Copenhagen Univ Hosp, Hvidovre, Denmark

[4] Copenhagen Univ Hosp, Glostrup, Denmark

[5] Rigshosp, Copenhagen Univ Hosp, DK-2100 Copenhagen, Denmark

[6] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[7] DANBIO Registry, Gentofte, Denmark

[8] Copenhagen Univ Hosp, Gentofte, Denmark

[9] Viborg Hosp, Viborg, Denmark

[10] Copenhagen Univ Hosp, Frederiksberg, Denmark

[11] Odense Univ Hosp, DK-5000 Odense, Denmark

[12] Univ So Denmark, Grasten, Denmark

[13] Aarhus Univ Hosp, Aalborg, Denmark

[14] Horsholm Hosp, Horsholm, Denmark

[15] Inst Publ Hlth, Odense, Denmark

来源：

ARTHRITIS AND RHEUMATISM | 2010年 / 62卷 / 09期

关键词：

D O I：

10.1002/art.27609

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2826 / 2828

页数：5

共 50 条

[21] Anticitrulline antibody assay specificity for rheumatoid arthritis: comment on the article by Schellekens et al - Reply
Hazes, JMM
van Venrooij, WJ
ARTHRITIS AND RHEUMATISM, 2000, 43 (08): : 1902 - 1902
[22] Diagnostic value of Doppler ultrasonography in rheumatoid arthritis: comment on the article by Weidekamm et al - Reply
Weidekamm, C
ARTHRITIS AND RHEUMATISM, 2004, 50 (02): : 677 - 678
[23] Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et al - Reply
Bresnihan, B
Alvaro-Gracia, JM
Cobby, M
Doherty, M
Domljan, Z
Emery, P
Nuki, G
Pavelka, K
Rau, R
Rozman, B
Watt, I
Williams, B
Aitchison, R
McCabe, D
Musikic, P
ARTHRITIS AND RHEUMATISM, 1999, 42 (08): : 1782 - 1782
[24] Novel approaches to discovery of biomarkers in rheumatoid arthritis: comment on the article by Oswald et al Reply
Gregersen, Peter K.
Oswald, Michaela
Curran, Mark
Carulli, John
ARTHRITIS & RHEUMATOLOGY, 2015, 67 (08) : 2277 - 2277
[25] Is the "lipid paradox" in rheumatoid arthritis really a paradox? Comment on the article by Bartels et al Reply
Bartels, Christie M.
Everett, Christine
McBride, Patrick
Smith, Maureen
Kind, Amy J. H.
Mell, Matthew
ARTHRITIS AND RHEUMATISM, 2011, 63 (11): : 3645 - 3646
[26] DOWN-TITRATION AND DISCONTINUATION OF INFLIXIMAB, ADALIMUMAB AND ETANERCEPT IN ESTABLISHED RHEUMATOID ARTHRITIS
Lojo, L.
Bonilla, G.
Peiteado, D.
Villalba, A.
Plasencia, C.
Nuno, L.
Balsa, A.
Martin-Mola, E.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 237 - 237
[27] THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS
Lawson, R. W.
Heatley, R. M.
Johnson, K., I
Khandker, R. K.
Singh, A.
VALUE IN HEALTH, 2010, 13 (07) : A308 - A308
[28] Dosing patterns and costs of adalimumab, etanercept, and infliximab among patients with rheumatoid arthritis
Engel-Nitz, N. M.
Huang, X.
Globe, D.
Baumgartner, S.
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 260 - 260
[29] COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB
Garces, K.
Thorne, C.
Boire, G.
Chow, A.
Poulin-Costello, M.
Walker, V
Haraoui, B.
VALUE IN HEALTH, 2016, 19 (03) : A229 - A230
[30] Incidence of vasculitis in rheumatoid arthritis:: comment on the article by Turesson et al
Puéchal, X
ARTHRITIS AND RHEUMATISM, 2005, 52 (05): : 1620 - 1620

← 1 2 3 4 5 →